The Cancer Animal Models Shared Resource (Mouse SR; Categories 1.02, 1.04, 1.06) of Winship Cancer Institute of Emory University (Winship) was established in 2012 to promote cancer discovery by providing expertise to Winship investigators in the development and analysis of animal models of cancer, with a particular focus on genetically engineered mouse models (GEMMs). Since its inception, Mouse SR has supported investigators across all four Winship programs (Cancer Genetics and Epigenetics (CGE), Cancer Cell Biology (CCB), Discovery and Developmental Therapeutics (DDT), and Cancer Prevention and Control (CPC)) with genetic mouse models of colon, prostate, breast, pancreatic, and lung cancer and brain tumors. The number of Winship members actively using Mouse SR increased during the current funding period from seven to twenty- one individual investigators. In 2014, Winship appointed a new Mouse SR Director and added an additional full- time staff member. Mouse SR has expanded its services to include cell-line and patient-derived orthotopic xenograft models and has acquired an IVIS Spectrum pre-clinical optical imaging system. The IVIS Spectrum is capable of detecting high-resolution bioluminescent and fluorescent sources deep within the animal and allows for longitudinal monitoring of therapeutic responses in vivo. Mouse SR provides a significant cost savings to Winship investigators by offering a source of centralized expertise and equipment. Future goals of Mouse SR include establishing immune-competent syngeneic models to support testing of immunotherapies and to establish a bank of GEMM-derived cells lines for rapid in vitro compound screening prior to in vivo studies. During the current funding period, Mouse SR has supported multiple grant applications and awards, contributed to high- impact publications, and supported the successful submission for two new multi-PI R01s and a U01 award. To further support Winship's programmatic initiatives, Mouse SR proposes to: 1) support outstanding cancer research by providing access to high quality services and technologies that promote scientific collaboration and translational potential and 2) provide the outstanding in vivo imaging technologies and associated expertise in support of pre-clinical animal model research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
Domestic Higher Education
United States
Zip Code
Danish, Hasan; Ferris, Matthew J; Balagamwala, Ehsan et al. (2018) Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma. Melanoma Res 28:120-125
Barwick, Benjamin G; Scharer, Christopher D; Martinez, Ryan J et al. (2018) B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation. Nat Commun 9:1900
Liu, Fakeng; Liu, Yuan; Liu, Xiuju et al. (2018) Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer 123:36-43
Kennedy, E M; Powell, D R; Li, Z et al. (2018) Galactic Cosmic Radiation Induces Persistent Epigenome Alterations Relevant to Human Lung Cancer. Sci Rep 8:6709
Xiao, Canhua; Beitler, Jonathan J; Higgins, Kristin A et al. (2018) Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. Brain Behav Immun 74:291-295
Cassidy, Richard J; Zhang, Xinyan; Switchenko, Jeffrey M et al. (2018) Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124:775-784
Jhaveri, Jaymin; Chowdhary, Mudit; Zhang, Xinyan et al. (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg :1-7
Jhaveri, Jaymin; Rayfield, Lael; Liu, Yuan et al. (2018) Impact of intensity modulated radiation therapy on survival in anal cancer. J Gastrointest Oncol 9:618-630
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697

Showing the most recent 10 out of 331 publications